Hydrocortisone Linked to 65% Lower Mortality in Severe CAP, While Other Corticosteroids Show No Benefit
Key Insights
A network meta-analysis of 11 RCTs with 2,042 patients found only hydrocortisone significantly reduced all-cause mortality in severe community-acquired pneumonia (search), with an approximate 65% relative risk reduction versus placebo.
Dexamethasone, methylprednisolone, and prednisolone did not demonstrate statistically significant mortality benefits, though no head-to-head comparisons were available to confirm superiority of any agent.
Low-to-moderate dosing and short-course regimens were associated with lower mortality and reduced need for mechanical ventilation, but evidence certainty was rated very low to low.
Hydrocortisone was associated with significantly lower all-cause mortality among patients with severe community-acquired pneumonia (search) (CAP), while dexamethasone, methylprednisolone, and prednisolone failed to demonstrate the same effect, according to a new network meta-analysis published by researchers from The First Hospital of Changsha, China.
The analysis, which pooled data from 11 randomized controlled trials encompassing 2,042 patients, found that hydrocortisone was the only corticosteroid linked to a statistically significant mortality reduction compared with placebo. The network estimate suggested an approximately 65% relative reduction in mortality risk. Hydrocortisone was also associated with a reduced need for mechanical ventilation.
"Hydrocortisone significantly reduced mortality, whereas methylprednisolone, dexamethasone, and prednisolone did not exhibit the same effect," wrote lead study researcher Liangdong Zhu and colleagues.
Study Design and Patient Population
Severe CAP was defined across the included trials as CAP requiring intensive care unit admission, meeting American Thoracic Society/Infectious Diseases Society of America criteria, having a PaO2/FiO2 ratio less than 300, or a pneumonia severity index score of IV or higher. All included trials compared a corticosteroid against placebo, creating what the researchers described as a "star-shaped" network that prevented direct head-to-head comparisons among the different corticosteroids.
The findings build on prior evidence from the CAPE COD trial, which had previously reported lower 28-day mortality with hydrocortisone among critically ill patients with severe CAP.
Subgroup Analyses and Dosing Patterns
Subgroup analyses suggested that low-to-moderate corticosteroid doses and short-course treatment were associated with lower mortality and reduced need for mechanical ventilation compared with placebo. However, the researchers emphasized that these exploratory findings should be interpreted cautiously because of limited statistical power and heterogeneity across studies.
Safety Profile
The researchers reported no statistically significant differences in serious adverse events between corticosteroid-treated groups and placebo. Reported adverse events included opportunistic infections, cardiac events, neuropsychiatric symptoms, acute renal failure, gastrointestinal bleeding, and hyperglycemia. Notably, the included trials did not consistently report secondary infections, fungal infections, or antibiotic-resistant pathogens, leaving gaps in the safety data.
Evidence Certainty and Limitations
The certainty of evidence for mortality, mechanical ventilation, and serious adverse events was rated very low to low. According to the researchers, these low ratings were driven largely by imprecision, heterogeneity, and reliance on indirect comparisons.
Additional limitations included variability in severe CAP definitions, corticosteroid dosing strategies, treatment duration, adverse-event reporting, comorbidities, and intensive care unit admission status across studies. Sensitivity analyses were not feasible because of the limited number of randomized trials and the network structure.
The researchers concluded that the findings were "not yet robust enough to warrant immediate changes to current treatment guidelines."
Broader Context in Severe Respiratory Illness
The findings align with a broader systematic review and meta-analysis by Soumare and colleagues, published in the Annals of Internal Medicine, which examined 20 studies including 3,459 patients with severe pneumonia or acute respiratory distress syndrome (search) (ARDS). That analysis found that low-dose (3 mg/kg per day or less), short-course (15 days or less) corticosteroids reduced short-term mortality in severe pneumonia (RR, 0.73; 95% CI, 0.57 to 0.93) and ARDS (RR, 0.77; CI, 0.61 to 0.99), without a statistically significant increase in hospital-acquired infections or secondary pneumonia.
The Soumare meta-analysis was similarly limited by heterogeneity between studies in defining pneumonia severity and in the type and duration of steroid used, though I² values assessing heterogeneity were generally acceptable. Data on long-term mortality beyond six months were not available.
Taken together, the evidence suggests a potential role for adjunctive, low-dose, short-course corticosteroids in severe pneumonia and ARDS, though the specific agent may matter—with hydrocortisone currently holding the strongest signal for mortality benefit in severe CAP. The researchers reported no competing interests.